AI platform to unencumber new categories of anti-sense oligonucleotide remedies
Deep Genomics, the AI pushed genetic medication corporate, gained a USD $13 million fairness funding led by way of Khosla Ventures, probably the most most sensible challenge capital corporations. They’re accompanied by way of early degree funding company True Ventures.
Deep Genomics joins Khosla Ventures’ portfolio, which incorporates Local weather Company, Editas Medication, Guardant Well being and Sq.. “Khosla Ventures is easily aligned with our project to construct a brand new more or less world-class genetic medication corporate,” mentioned Brendan Frey, CEO and medical founding father of Deep Genomics. “An organization whose founding theory is that the way forward for medication will depend on synthetic intelligence, as a result of biology is just too complicated for people to grasp.”
Within the subsequent 3 years, Deep Genomics will use its platform to unencumber new categories of anti-sense oligonucleotide remedies that have been in the past inaccessible, and advance them for medical analysis. “We consider that the era evolved at Deep Genomics places them in a singular place to spot new remedies,” mentioned Founding Spouse Vinod Khosla. “On account of the standard in their science and engineering staff and the deep integration in their AI era into their preclinical drug building pipeline, we’re assured very huge possible exists right here.”
Deep Genomics is construction a biologically correct data- and AI-driven platform that helps geneticists, molecular biologists and chemists within the building of remedies.
In venture Saturn, named after the god of lots and renewal, the platform might be used to look throughout a limiteless area of over 69 billion molecules and to generate a library of 1000 compounds that can be utilized to exactly manipulate cellular biology. This era will permit Deep Genomics to spot preclinical applicants and to advance them for medical analysis in collaboration with stakeholders.